Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rodney J Hicks

Showing results (361-370 of 471) with videos related to

Pageof 48
Sort By:
The Journal of Clinical Endocrinology and Metabolism|January 9, 2013
Improving diagnosis of tumor-induced osteomalacia with Gallium-68 DOTATATE PET/CTRoderick J Clifton-Bligh, Michael S Hofman, Emma Duncan, et al.
BJU International|May 5, 2018
A prospective randomized multicentre study of the impact of gallium-68 prostate-specific membrane antigen (PSMA) PET/CT imaging for staging high-risk prostate cancer prior to curative-intent surgery or radiotherapy (proPSMA study): clinical trial protocolMichael S Hofman, Declan G Murphy, Scott G Williams, et al.
European Journal of Nuclear Medicine and Molecular Imaging|March 7, 2020
Prognostic biomarkers in men with metastatic castration-resistant prostate cancer receiving [177Lu]-PSMA-617Justin Ferdinandus, John Violet, Shahneen Sandhu, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|July 3, 2015
Pulmonary Scintigraphy for the Diagnosis of Acute Pulmonary Embolism: A Survey of Current Practices in Australia, Canada, and FrancePierre-Yves Le Roux, Matthieu Pelletier-Galarneau, Romain De Laroche, et al.
European Journal of Nuclear Medicine and Molecular Imaging|June 14, 2019
PET-detected pneumonitis following curative-intent chemoradiation in non-small cell lung cancer (NSCLC): recognizing patterns and assessing the impact on the predictive ability of FDG-PET/CT response assessmentAmir Iravani, Guy-Anne Turgeon, Tim Akhurst, et al.
European Journal of Nuclear Medicine and Molecular Imaging|March 26, 2025
Safety and efficacy of re-treatment with [<sup>177</sup>Lu]Lu-DOTA-Octreotate radionuclide therapy in progressive gastro-entero-pancreatic neuroendocrine tumours - a single centre experienceRaghava Kashyap, Ramin Alipour, Emma Boehm, et al.
Bioconjugate Chemistry|December 15, 2016
Enhancing PET Signal at Target Tissue in Vivo: Dendritic and Multimeric Tris(hydroxypyridinone) Conjugates for Molecular Imaging of α<sub>v</sub>β<sub>3</sub> Integrin Expression with Gallium-68Cinzia Imberti, Samantha Y A Terry, Carleen Cullinane, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 12, 2012
Evaluation of circulating tumor cells and circulating tumor DNA in non-small cell lung cancer: association with clinical endpoints in a phase II clinical trial of pertuzumab and erlotinibElizabeth A Punnoose, Siminder Atwal, Weiqun Liu, et al.
Journal of Medicinal Chemistry|August 14, 2020
Bivalent Inhibitors of Prostate-Specific Membrane Antigen Conjugated to Desferrioxamine B Squaramide Labeled with Zirconium-89 or Gallium-68 for Diagnostic Imaging of Prostate CancerAsif Noor, Jessica K Van Zuylekom, Stacey E Rudd, et al.
EJNMMI Physics|June 1, 2017
EORTC PET response criteria are more influenced by reconstruction inconsistencies than PERCIST but both benefit from the EARL harmonization programCharline Lasnon, Elske Quak, Pierre-Yves Le Roux, et al.
Pageof 48

Showing results (361-370 of 471) with videos related to

Sort By:
Pageof 48
The Journal of Clinical Endocrinology and Metabolism|January 9, 2013
Improving diagnosis of tumor-induced osteomalacia with Gallium-68 DOTATATE PET/CTRoderick J Clifton-Bligh, Michael S Hofman, Emma Duncan, et al.
BJU International|May 5, 2018
A prospective randomized multicentre study of the impact of gallium-68 prostate-specific membrane antigen (PSMA) PET/CT imaging for staging high-risk prostate cancer prior to curative-intent surgery or radiotherapy (proPSMA study): clinical trial protocolMichael S Hofman, Declan G Murphy, Scott G Williams, et al.
European Journal of Nuclear Medicine and Molecular Imaging|March 7, 2020
Prognostic biomarkers in men with metastatic castration-resistant prostate cancer receiving [177Lu]-PSMA-617Justin Ferdinandus, John Violet, Shahneen Sandhu, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|July 3, 2015
Pulmonary Scintigraphy for the Diagnosis of Acute Pulmonary Embolism: A Survey of Current Practices in Australia, Canada, and FrancePierre-Yves Le Roux, Matthieu Pelletier-Galarneau, Romain De Laroche, et al.
European Journal of Nuclear Medicine and Molecular Imaging|June 14, 2019
PET-detected pneumonitis following curative-intent chemoradiation in non-small cell lung cancer (NSCLC): recognizing patterns and assessing the impact on the predictive ability of FDG-PET/CT response assessmentAmir Iravani, Guy-Anne Turgeon, Tim Akhurst, et al.
European Journal of Nuclear Medicine and Molecular Imaging|March 26, 2025
Safety and efficacy of re-treatment with [<sup>177</sup>Lu]Lu-DOTA-Octreotate radionuclide therapy in progressive gastro-entero-pancreatic neuroendocrine tumours - a single centre experienceRaghava Kashyap, Ramin Alipour, Emma Boehm, et al.
Bioconjugate Chemistry|December 15, 2016
Enhancing PET Signal at Target Tissue in Vivo: Dendritic and Multimeric Tris(hydroxypyridinone) Conjugates for Molecular Imaging of α<sub>v</sub>β<sub>3</sub> Integrin Expression with Gallium-68Cinzia Imberti, Samantha Y A Terry, Carleen Cullinane, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 12, 2012
Evaluation of circulating tumor cells and circulating tumor DNA in non-small cell lung cancer: association with clinical endpoints in a phase II clinical trial of pertuzumab and erlotinibElizabeth A Punnoose, Siminder Atwal, Weiqun Liu, et al.
Journal of Medicinal Chemistry|August 14, 2020
Bivalent Inhibitors of Prostate-Specific Membrane Antigen Conjugated to Desferrioxamine B Squaramide Labeled with Zirconium-89 or Gallium-68 for Diagnostic Imaging of Prostate CancerAsif Noor, Jessica K Van Zuylekom, Stacey E Rudd, et al.
EJNMMI Physics|June 1, 2017
EORTC PET response criteria are more influenced by reconstruction inconsistencies than PERCIST but both benefit from the EARL harmonization programCharline Lasnon, Elske Quak, Pierre-Yves Le Roux, et al.
Pageof 48